Japan is legendary for its focus—many would say obsession—on producing high-quality products. When it comes to sourcing active pharmaceutical ingredients (APIs), Japanese generic drug firms are ...

Japan’s pharmaceutical industry is undergoing a period of transformation, and the contract development and manufacturing organization (CDMO) of large molecule active pharmaceutical ingredients (APIs) ...

Ames Gross shares his insights into the opportunities in Japan's API market in his latest article. Asia's active pharmaceutical ingredient (API) market is growing at a rapid pace. From 2008 to 2012, ...

The increase in the development of new drugs in Japan which will create opportunities for both international partners and domestic manufacturers of active pharmaceutical ingredients (APIs ) and ...

Japan's government is looking to procure more generic drugs to help relieve its healthcare budget, and Eisai intends to cash in on that shift by offering its own India-made APIs to competitors. It is ...

For the second time in recent weeks, the FDA has slapped a Japanese API maker with a warning letter, this time predominantly for data integrity problems at Sekisui Medical. According to the warning, ...